Tissue Plasminogen Activator in Critically Ill Adults with COVID-19
Ann Am Thorac Soc
.
2021 Nov;18(11):1917-1921.
doi: 10.1513/AnnalsATS.202102-127RL.
Authors
David J Douin
1
,
Shahzad Shaefi
2
,
Samantha K Brenner
3
,
Shruti Gupta
4
,
Isabel Park
4
,
Franklin L Wright
1
,
Kusum S Mathews
5
,
Lili Chan
5
,
Hanny Al-Samkari
6
,
Sarah Orfanos
7
,
Jared Radbel
7
,
David E Leaf
4
Affiliations
1
University of Colorado School of Medicine Aurora, Colorado.
2
Beth Israel Deaconess Medical Center Boston, Massachusetts.
3
Hackensack University Medical Center Hackensack, New Jersey.
4
Brigham and Women's Hospital, Harvard Medical School Boston, Massachusetts.
5
Icahn School of Medicine at Mount Sinai New York, New York.
6
Massachusetts General Hospital Boston, Massachusetts.
7
Rutgers Robert Wood Johnson Medical School New Brunswick, New Jersey.
PMID:
33872546
PMCID:
PMC8641829
DOI:
10.1513/AnnalsATS.202102-127RL
No abstract available
Publication types
Letter
Research Support, N.I.H., Extramural
MeSH terms
Adult
COVID-19 Drug Treatment*
Critical Illness
Humans
Tissue Plasminogen Activator* / therapeutic use
Substances
Tissue Plasminogen Activator
Grants and funding
K08 GM134220/GM/NIGMS NIH HHS/United States
R01 DK125786/DK/NIDDK NIH HHS/United States
R01 HL144566/HL/NHLBI NIH HHS/United States
R03 AG060179/AG/NIA NIH HHS/United States
T32 GM135169/GM/NIGMS NIH HHS/United States
K08 ES031678/ES/NIEHS NIH HHS/United States
K23 HL130648/HL/NHLBI NIH HHS/United States
K23 DK124645/DK/NIDDK NIH HHS/United States